- Featured Product
- KD/KO Validated
MCL1 Polyclonal antibody
MCL1 Polyclonal Antibody for IHC, IP, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IP, IHC, IF, ELISA
Conjugate
Unconjugated
Cat no : 16225-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | Jurkat cells, K-562 cells, human liver tissue, human brain tissue, HEK-293T cells, A431 cells, mouse spleen tissue, Raji cells, HL-60 cells, MCF-7 cells, HeLa cells |
| Positive IP detected in | Raji cells |
| Positive IHC detected in | human tonsillitis tissue, human cervical cancer tissue, human lung cancer tissue, human pancreas tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Sample-dependent, check data in validation data gallery | |
Published Applications
| KD/KO | See 3 publications below |
| WB | See 50 publications below |
| IHC | See 6 publications below |
| IF | See 2 publications below |
| IP | See 2 publications below |
Product Information
16225-1-AP targets MCL1 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | MCL1 fusion protein Ag10397 |
| Full Name | myeloid cell leukemia sequence 1 (BCL2-related) |
| Calculated molecular weight | 350 aa, 37 kDa |
| Observed molecular weight | 35-40 kDa |
| GenBank accession number | BC107735 |
| Gene symbol | MCL1 |
| Gene ID (NCBI) | 4170 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. MCL-1 can be alternatively spliced into a long form (MCL-1L, 40 kDa) or a short form (MCL-1S, 30 kDa). (PMID: 15467463, PMID: 15147382)
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for MCL1 antibody 16225-1-AP | Download protocol |
| IHC protocol for MCL1 antibody 16225-1-AP | Download protocol |
| IP protocol for MCL1 antibody 16225-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Molecules Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. | ||
J Cell Mol Med MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways. | ||
Life Sci Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K/Akt/GSK3β pathway. | ||
Target Oncol Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. | ||
Bosn J Basic Med Sci CircRNA_014511 affects the radiosensitivity of bone marrow mesenchymal stem cells by binding to miR-29b-2-5p. | ||
EBioMedicine The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. |
